Effect of alanine supplementation on oxalate synthesis

Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects

BACKGROUND

The amino acid L-alanine, has been shown to be elevated in biofluids during major depression but its relevance remains unexplored.

AIM

We have investigated the effects of repeated L-alanine administration on emotional behaviours and central gene expression in mice.

METHODS

Mice received a daily, 2-week intraperitoneal injection of either saline or L-alanine at 100 or 200 mg/kg and were exposed to the open field, light-dark box and forced swim test. The expression of L-alanine transporters (asc-1, ASCT2), glycine receptor subunits (GlyRs), NMDA receptor subunits (GluNs) mRNAs were measured, together with western blots of the signalling protein mammalian target of rapamycin (mTOR). Since L-alanine modulates glucose homeostasis, peripheral and central metabolomes were evaluated with 1H-NMR.

RESULTS

L-alanine administration at 100 mg/kg, but not at 200 mg/kg, to both male and female mice increased latency to float and reduced floating time in the forced swim test, but had no effect on anxious behaviour in the open field and light-dark box tests. There was a significant reduction in mRNAs encoding asc-1 and ASCT2 and GluN2B in the hippocampus of mice following 100 mg/kg L-alanine only. On western blots, hippocampal GluN2B immunoreactivity was reduced, but mTOR signalling was increased in the 100 mg/kg L-alanine group. 1H-NMR revealed gender-specific changes in the forebrain, plasma and liver metabolomes only at 200 mg/kg of L-alanine.

CONCLUSIONS

Our data suggest that L-alanine may have antidepressant-like effect that may involve the modulation of glutamate neurotransmission independently of metabolism. In major depression, therefore, elevated L-alanine may be a homeostatic response to pathophysiological processes, though this will require further investigation.

Exploring the untapped practices in bacterial-fungal mixed-based cultures for acidic treatment of metal-enriched printed circuit board waste

This study explores the extraction of metals from spent mobile phone printed circuit boards (SMPhPCBs) to address environmental and resource depletion concerns. The challenges in metal recovery from SMPhPCBs arise due to their complex composition and high metal content. While previous research has primarily focused on using bio-cyanide, bio-sulfate, and bio-ferric compounds from acidophilic bacteria, the potential of bio-oxalic acid for SMPhPCBs treatment and the alteration of their complex structure has not yet been explored. Additionally, this study suggests evaluating the untapped potential of Aspergillus niger in oxalic acid production through mixed cultures with bacteria, marking a pioneering approach. A unique culture of Bacillus megaterium and A. niger was created, inducing bio-stress by bacterial metabolites, including gluconic acid (2683 mg/l) and live/dead bacterial cells in a medium with glucose deficiency. Results demonstrated reducing sugar consumption and oxalic acid over-production in mixed cultures compared to pure cultures, ranging from 1350 to 4951 mg/l at an initial glucose concentration (IGC) of 10 g/l and 4276 to 7460 mg/l at IGC 20 g/l. This over-production is attributed to proposed fungal signaling mechanisms to bacteria. Metal extraction using organic acids and siderophores at 10 g/l pulp density, 24 h, and 60 °C yielded Mn (100 %), Pt (100 %), Pd (70.7 %), Fe (50.8 %), Co (48.3 %), Al (21.8 %), among others. The final valuable residue containing copper, gold, and silver holds potential for future recycling. The study concludes with XRD and FTIR analyses to assess the bioleaching effect on the bio-leached powder.

The gut-joint axis mediates the TNF-induced RA process and PBMT therapeutic effects through the metabolites of gut microbiota

The gut-joint axis, one of the mechanisms that mediates the onset and progression of joint and related diseases through gut microbiota, and shows the potential as therapeutic target. A variety of drugs exert therapeutic effects on rheumatoid arthritis (RA) through the gut-joint axis. However, the anti-inflammatory and immunomodulatory effect of novel photobiomodulatory therapy (PBMT) on RA need further validation and the involvement of gut-joint axis in this process remains unknown. The present study demonstrated the beneficial effects of PBMT on RA, where we found the restoration of gut microbiota homeostasis, and the related key pathways and metabolites after PBMT. We also discovered that the therapeutic effects of PBMT on RA mainly through the gut-joint axis, in which the amino acid metabolites (Alanine and N-acetyl aspartate) play the key role and rely on the activity of metabolic enzymes in the target organs. Together, the results prove that the metabolites of amino acid from gut microbiota mediate the regulation effect on the gut-joint axis and the therapeutic effect on rheumatoid arthritis of PBMT.

Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD+)

L-alanine possesses extensive physiological functionality and tremendous pharmacological significance, therefore could be considered as potential ingredient for food, pharmaceutical, and personal care products. However, therapeutic properties of L-alanine still need to be addressed in detail to further strengthen its utilization as a viable ingredient for developing natural therapeutics with minimum side effects. Thus, the present study was aimed to explore the anticipated therapeutic potential of L-alanine, produced microbially using a lactic acid bacterial strain Pediococcus acidilactici BD16 (alaD⁺) expressing L-alanine dehydrogenase enzyme. The anticipated therapeutic potential of L-alanine was assessed in terms of anti-proliferative, anti-bacterial, and anti-urolithiatic properties. Anti-bacterial assays revealed that L-alanine successfully inhibited growth and in vitro proliferation of important human pathogens including Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutans, and Vibrio cholerae in a concentration-dependent manner. Current investigation has also revealed its significant anti-proliferative potential against human lung adenocarcinoma (A549; IC₅₀ 7.32 μM) and mammary gland adenocarcinoma (MCF-7; IC₅₀ 8.81 μM) cells. The anti-urolithiatic potential of L-alanine was augmented over three different phases, viz., nucleation inhibition, aggregation inhibition, and oxalate depletion. Further, an in vitro cell culture-based kidney stone dissolution model using HEK293-T cells was also established to further strengthen its anti-urolithiatic potential. This is probably the first in vitro cell culture-based model which experimentally validates the immense therapeutic efficacy of L-alanine in treating urolithiasis disease. KEY POINTS: • Assessment of therapeutic potential of L-alanine produced by LAB. • L-alanine exhibited significant anti-proliferative and anti-bacterial activities. • L-alanine as potential anti-urolithiatic agent.